Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05914116




Registration number
NCT05914116
Ethics application status
Date submitted
13/06/2023
Date registered
22/06/2023
Date last updated
27/11/2024

Titles & IDs
Public title
A Study of DB-1311 in Advanced/Metastatic Solid Tumors
Scientific title
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors
Secondary ID [1] 0 0
DB-1311-O-1001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - DB-1311

Experimental: DB-1311 Dose Level 1 - Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 1 on Day 1 of each cycle Q3W

Experimental: DB-1311 Dose Level 2 - Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 2 on Day 1 of each cycle Q3W

Experimental: DB-1311 Dose Level 3 - Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 3 on Day 1 of each cycle Q3W

Experimental: DB-1311 Dose Level 4 - Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 4 on Day 1 of each cycle Q3W

Experimental: DB-1311 Dose Level 5 - Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 5 on Day 1 of each cycle Q3W

Experimental: DB-1311 Dose Expansion 1 - Subjects with advanced/unresectable, or metastatic SCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.

Experimental: DB-1311 Dose Expansion 2 - Subjects with advanced/unresectable, or metastatic NSCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.

Experimental: DB-1311 Dose Expansion 3 - Subjects with advanced/unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.

Experimental: DB-1311 Dose Expansion 4 - Subjects with advanced/unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.

Experimental: DB-1311 Dose Expansion 5 - Subjects with advanced/unresectable, or metastatic melanoma who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.

Experimental: DB-1311 Dose Expansion 6 - Subjects with advanced/unresectable, or metastatic HCC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.

Experimental: DB-1311 Dose Expansion 7 - Subjects with advanced/unresectable, or metastatic cervical cancer who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.

Experimental: DB-1311 Dose Expansion 8 - Subjects with other advanced or metastatic solid tumors who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.


Treatment: Drugs: DB-1311
Administered I.V.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0. Percentage of participants in Part 1 with DLTs
Timepoint [1] 0 0
up to 21 days after Cycle 1 Day 1
Primary outcome [2] 0 0
Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.
Timepoint [2] 0 0
Up to follow-up period, approximately 1 year post-treatment
Primary outcome [3] 0 0
Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.
Timepoint [3] 0 0
Up to follow-up period, approximately 1 year post-treatment
Primary outcome [4] 0 0
Maximum Tolerated Dose (MTD) of DB-1311
Timepoint [4] 0 0
Up to the completion of Part 1 (assessed up to 12 months)
Primary outcome [5] 0 0
Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1311
Timepoint [5] 0 0
Up to the completion of Part 1 (assessed up to 12 months)
Primary outcome [6] 0 0
Phase 2a: Percentage of Participants with Treatment Emergent adverse events (TEAEs) as assessed by CTCAE v5.0.
Timepoint [6] 0 0
Up to follow-up period, approximately 1 year post-treatment
Primary outcome [7] 0 0
Phase 2a: Percentage of participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.
Timepoint [7] 0 0
Up to follow-up period, approximately 1 year post-treatment
Primary outcome [8] 0 0
Phase 2a: Objective Response Rate (ORR) as determined by investigator
Timepoint [8] 0 0
Up to follow-up period, approximately 1 year post-treatment
Secondary outcome [1] 0 0
Phase 1: Objective response rate (ORR)
Timepoint [1] 0 0
Up to follow-up period, approximately 1 year post-treatment
Secondary outcome [2] 0 0
Phase 1 & Phase 2a: duration of response (DoR)
Timepoint [2] 0 0
Up to follow-up period, approximately 1 year post-treatment
Secondary outcome [3] 0 0
Phase 1 & Phase 2a: disease-control rate (DCR)
Timepoint [3] 0 0
Up to follow-up period, approximately 1 year post-treatment
Secondary outcome [4] 0 0
Phase 1 & Phase 2a: Time to Response (TTR)
Timepoint [4] 0 0
Up to follow-up period, approximately 1 year post-treatment
Secondary outcome [5] 0 0
Phase 1 & Phase 2a: Progression Free Survival (PFS)
Timepoint [5] 0 0
Up to follow-up period, approximately 1 year post-treatment
Secondary outcome [6] 0 0
Phase 1 & Phase 2a: Overall Survival (OS)
Timepoint [6] 0 0
From date of first dose until the date of death or lost to follow up, approximately 1 year post-treatment
Secondary outcome [7] 0 0
Prostate-specific antigen (PSA)
Timepoint [7] 0 0
From date of first dose until the date of first PSA progression, approximately 1 year post-treatment
Secondary outcome [8] 0 0
Phase 1 & Phase 2a: Pharmacokinetic-AUC
Timepoint [8] 0 0
within 8 cycles (each cycle is 21 days)
Secondary outcome [9] 0 0
Phase 1 & Phase 2a: Pharmacokinetic-Cmax
Timepoint [9] 0 0
within 8 cycles (each cycle is 21 days)
Secondary outcome [10] 0 0
Phase 1 & Phase 2a: Pharmacokinetic-Tmax
Timepoint [10] 0 0
within 8 cycles (each cycle is 21 days)
Secondary outcome [11] 0 0
Phase 1 & Phase 2a: Pharmacokinetic-Cthrough
Timepoint [11] 0 0
within 8 cycles (each cycle is 21 days)
Secondary outcome [12] 0 0
Phase 1 & 2a: Anti-drug antibody (ADA) prevalence
Timepoint [12] 0 0
Up to follow-up period, approximately 1 year post-treatment
Secondary outcome [13] 0 0
Phase 1 & 2a: ADA incidence
Timepoint [13] 0 0
Up to follow-up period, approximately 1 year post-treatment

Eligibility
Key inclusion criteria
1. Male or female adults (defined as = 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).
2. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment; or for which no standard treatment is available.
3. At least one measurable lesion as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) version 1.1 criteria. Castrate-resistant prostate cancer (CRPC) participants with bone only disease may be eligible on a case-by- case basis after discussion with the Medical Monitor.
4. Has a life expectancy of = 3 months.
5. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
6. Has LVEF = 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.
7. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of B7-H3 level and other biomarkers if no contraindication.

Note: there is no minimum B7-H3 expression level mandatory for entry into the study.
8. Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.
9. Male and female subjects of reproductive/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) during the study and for at least 4 months and 7 months after the last dose of study drug, respectively.
10. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration.
11. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.
12. SCLC participants (Phase 2a Cohort 1 ONLY):

* Pathologically documented locally advanced, or metastatic SCLC not amenable to curative surgery or radiation.
* Prior therapy with at least one platinum-based line as systemic therapy for extensivestage disease with at least two cycles of therapy (except in the case of early objective PD).
* Prior treatment regimens with irinotecan, topotecan or any other TOP I inhibitor including investigational TOP I inhibitors are not allowed.
13. NSCLC participants (Phase 2a Cohort 2 ONLY):

* Pathologically documented locally advanced, or metastatic NSCLC and is not amenable to curative surgery or radiation.
* Has received prior treatment with platinum-based chemotherapy regimen and/or anti-PD-1/PD-L1 antibody-based regimen in the advanced/unresectable, or metastatic setting unless unable or unwilling. Participants with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (e.g., ALK rearrangement, ROS1 rearrangement, KRAS G12C mutation, BRAF V600E mutation, NTRK1/2/3 Gene fusion, MET Exon 14 skipping, RET rearrangement etc.) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy.
14. ESCC participants (Phase 2a Cohort 3 ONLY):

* Pathologically documented locally advanced, or metastatic ESCC and is not amenable to curative surgery or radiation.
* Having received at least one prior therapy for unresectable disease. Patients with recurrence within 6 months of completion of neoadjuvant or adjuvant therapy will be considered as having received one prior therapy for unresectable disease.
15. CRPC participants (Phase 2a Cohort 4 ONLY):

* Pathologically documented metastatic adenocarcinoma of the prostate cancer.
* Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone < 50 ng/dL AND 2) progressive disease as defined by PCWG3 criteria.
* Having received prior docetaxel (before or after an AR-targeted therapy). Docetaxel rechallenge was allowed.
* Having received prior novel hormone therapy.
16. Melanoma participants (Phase 2a Cohort 5 ONLY)

• Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy, must have had either:
* Previously treated with a PD-1 or PD-L1 inhibitor.
* If participants with BRAF gene mutant melanoma, must have had a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene and/or mitogen-activated protein kinase (MEK) protein inhibitor.
17. HCC participants (Phase 2a Cohort 6 ONLY)

* Histological/cytological confirmed diagnosis of HCC or clinically confirmed diagnosis of HCC as per American Association for the Study of Liver Diseases (AASLD) criteria, and:
* Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic disease;
* Has experienced disease progression during or after treatment with an anti-PD-1/L1 agent administered either as monotherapy or in combination.

Note: Subjects basically should receive prior standard therapy.

• However, if the investigator judges the therapy is not appropriate for the subject, the prior standard therapy is not necessarily mandated for the eligibility.
18. Cervical cancer participants (Phase 2a Cohort 7 ONLY)

* Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and:
* Has experienced disease progression during or after treatment with a standard of care systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as either:

d. paclitaxel + cisplatin + bevacizumab + anti-PD-(L)1 agent, or e. paclitaxel + carboplatin + bevacizumab + anti-PD-(L)1 agent, or f. paclitaxel + topotecan + bevacizumab + anti-PD-(L)1 agent Note: In cases where bevacizumab and/or anti-PD-(L)1 agent is not a standard of care therapy or the subject was ineligible for such treatment according to local standards, prior treatment with bevacizumab and/or anti-PD-(L)1 agent is not required.
* Has received 1 or 2 prior systemic therapy regimens for recurrent or metastatic cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a systemic therapy regimen. Single agent therapy with an anti-PD(L)1 agent for recurrent or metastatic cervical cancer should be counted.
19. Participants with other solid tumors (Phase 2a Cohort 8 ONLY)

* Histologically or cytologically confirmed solid tumors.
* Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311 are available prior to consenting to participate in this trial).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Unless otherwise specified, the exclusion criteria are common to both Phase 1 and Phase 2a. Subjects who meet any of the following criteria will be excluded from the study:

1. Prior treatment with B7-H3 targeted therapy.
2. Prior treatment with antibody drug conjugate with topoisomerase inhibitor (e.g., trastuzumab deruxtecan).
3. Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.
4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.
5. Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to > 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate.
6. Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval.
7. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
8. Has a history of underlying pulmonary disorder including, but not limited to, pulmonary emboli within 3 months of the start of study treatment, severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary compromise or requirement for supplemental oxygen.
9. Clinically significant gastrointestinal disorder including, but not limited to, history of gastrointestinal fistulation that need long-term intravenous nutrition; gastrointestinal dysfunction that need long-term enteral nutrition through the tube feeding; gastrointestinal obstruction/perforation that not recovered within 6 months prior to the enrollment.
10. Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the enrollment.
11. Any autoimmune, connective tissue or inflammatory disorders (e.g., rheumatoid arthritis, Sjögren's, sarcoidosis) where there is documented, or a suspicion of pulmonary involvement at the time of screening.
12. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.
13. Know human immunodeficiency virus (HIV) infection.
14. Subjects have active viral (any etiology) hepatitis are excluded. However, subjects with serologic evidence of chronic hepatitis B virus (HBV) infection (defined by a positive hepatitis B surface antigen [HBsAg] test or a positive hepatitis B core antibody test) who have a viral load below the limit quantification (HBV DNA titer < 1000 cps/mL or 200 IU/mL) and are not currently on viral suppressive therapy may be eligible and should be discussed with the Sponsor's Medical Monitor. However, subjects with a history of hepatitis C virus (HCV) infection who have completed curative antiviral treatment and have a viral load below the limit of quantification are eligible for study entry.
15. Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by pregnancy tests performed within 7 days prior to enrollment.
16. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study randomization.
17. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE version 5.0, grade = 1 or baseline. Subjects with chronic Grade 2 toxicities (e.g., Grade 2 neuropathy) may be eligible based on the discussion and agreement between Investigator and Sponsor.
18. Has multiple primary malignancies within 3 years before enrollment, except adequately resected non-melanoma skin cancer (e.g., resected basal or squamous cell skin cancer), curatively treated in-situ disease (e.g., carcinoma in situ of the cervix or breast), other solid tumors curatively treated (e.g., superficial bladder cancer), or contralateral breast cancer.
19. Has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation or evaluation of the clinical study in the opinion of the investigator.
20. Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product.
21. Patients with other reasons that, in the opinion of the Investigator, make them unsuitable to participate in this study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/09/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2026
Actual
Sample size
Target
450
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
Research Site 208 - Blacktown
Recruitment hospital [2] 0 0
Research Site 215 - Camperdown
Recruitment hospital [3] 0 0
Research Site 212 - Concord
Recruitment hospital [4] 0 0
Research Site 217 - New Lambton Heights
Recruitment hospital [5] 0 0
Research Site 201 - Sydney
Recruitment hospital [6] 0 0
Research Site 205 - Sydney
Recruitment hospital [7] 0 0
Research Site 206 - Sydney
Recruitment hospital [8] 0 0
Research Site 216 - Waratah
Recruitment hospital [9] 0 0
Research Site 209 - Birtinya
Recruitment hospital [10] 0 0
Research Site 203 - Brisbane
Recruitment hospital [11] 0 0
Research Site 210 - Gold Coast
Recruitment hospital [12] 0 0
Research Site 202 - Nedlands
Recruitment hospital [13] 0 0
Research Site 207 - Nedlands
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
2139 - Concord
Recruitment postcode(s) [4] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [5] 0 0
2031 - Sydney
Recruitment postcode(s) [6] 0 0
2109 - Sydney
Recruitment postcode(s) [7] 0 0
2228 - Sydney
Recruitment postcode(s) [8] 0 0
2298 - Waratah
Recruitment postcode(s) [9] 0 0
4575 - Birtinya
Recruitment postcode(s) [10] 0 0
4102 - Brisbane
Recruitment postcode(s) [11] 0 0
4224 - Gold Coast
Recruitment postcode(s) [12] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Nevada
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
South Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Virginia
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
China
State/province [14] 0 0
Anhui
Country [15] 0 0
China
State/province [15] 0 0
Beijing
Country [16] 0 0
China
State/province [16] 0 0
Chongqing
Country [17] 0 0
China
State/province [17] 0 0
Fujian
Country [18] 0 0
China
State/province [18] 0 0
Guangdong
Country [19] 0 0
China
State/province [19] 0 0
Hebei
Country [20] 0 0
China
State/province [20] 0 0
Heilongjiang
Country [21] 0 0
China
State/province [21] 0 0
Henan
Country [22] 0 0
China
State/province [22] 0 0
Hubei
Country [23] 0 0
China
State/province [23] 0 0
Hunan
Country [24] 0 0
China
State/province [24] 0 0
Jiangsu
Country [25] 0 0
China
State/province [25] 0 0
Jiangxi
Country [26] 0 0
China
State/province [26] 0 0
Jilin
Country [27] 0 0
China
State/province [27] 0 0
Liaoning
Country [28] 0 0
China
State/province [28] 0 0
Shandong
Country [29] 0 0
China
State/province [29] 0 0
Shanghai
Country [30] 0 0
China
State/province [30] 0 0
Shanxi
Country [31] 0 0
China
State/province [31] 0 0
Sichuan
Country [32] 0 0
China
State/province [32] 0 0
Tianjin
Country [33] 0 0
China
State/province [33] 0 0
Zhejiang
Country [34] 0 0
Taiwan
State/province [34] 0 0
Kaohsiung
Country [35] 0 0
Taiwan
State/province [35] 0 0
New Taipei City
Country [36] 0 0
Taiwan
State/province [36] 0 0
Taipei
Country [37] 0 0
Taiwan
State/province [37] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
DualityBio Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
BioNTech SE
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.
Trial website
https://clinicaltrials.gov/study/NCT05914116
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Lily Hu
Address 0 0
DualityBio Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Michael Sun
Address 0 0
Country 0 0
Phone 0 0
86-21-26018730
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05914116